477 related articles for article (PubMed ID: 16914693)
1. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
Kappos L; Polman CH; Freedman MS; Edan G; Hartung HP; Miller DH; Montalban X; Barkhof F; Bauer L; Jakobs P; Pohl C; Sandbrink R
Neurology; 2006 Oct; 67(7):1242-9. PubMed ID: 16914693
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
[TBL] [Abstract][Full Text] [Related]
3. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.
Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Bauer L; Dahms S; Lanius V; Pohl C; Sandbrink R;
Lancet; 2007 Aug; 370(9585):389-97. PubMed ID: 17679016
[TBL] [Abstract][Full Text] [Related]
4. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.
Polman C; Kappos L; Freedman MS; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Selmaj K; Uitdehaag BM; Dahms S; Bauer L; Pohl C; Sandbrink R;
J Neurol; 2008 Apr; 255(4):480-7. PubMed ID: 18004635
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
[TBL] [Abstract][Full Text] [Related]
6. Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study.
Freedman MS; De Stefano N; Barkhof F; Polman CH; Comi G; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Lehr L; Stubinski B; Jack DL; Kappos L
J Neurol; 2014 Mar; 261(3):490-9. PubMed ID: 24413638
[TBL] [Abstract][Full Text] [Related]
7. MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.
Nielsen JM; Pohl C; Polman CH; Barkhof F; Freedman MS; Edan G; Miller DH; Bauer L; Sandbrink R; Kappos L; Uitdehaag BM
BMC Neurol; 2009 May; 9():19. PubMed ID: 19457248
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
Barkhof F; Polman CH; Radue EW; Kappos L; Freedman MS; Edan G; Hartung HP; Miller DH; Montalbán X; Poppe P; de Vos M; Lasri F; Bauer L; Dahms S; Wagner K; Pohl C; Sandbrink R
Arch Neurol; 2007 Sep; 64(9):1292-8. PubMed ID: 17846268
[TBL] [Abstract][Full Text] [Related]
9. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
10. Interferon-beta-1b: in newly emerging multiple sclerosis.
McKeage K
CNS Drugs; 2008; 22(9):787-92. PubMed ID: 18698876
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
Comi G; De Stefano N; Freedman MS; Barkhof F; Uitdehaag BM; de Vos M; Marhardt K; Chen L; Issard D; Kappos L
J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):285-294. PubMed ID: 28039317
[TBL] [Abstract][Full Text] [Related]
12. Interferon-β-1b: a review of its use in multiple sclerosis.
Plosker GL
CNS Drugs; 2011 Jan; 25(1):67-88. PubMed ID: 21128695
[TBL] [Abstract][Full Text] [Related]
13. Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
Nagtegaal GJ; Pohl C; Wattjes MP; Hulst HE; Freedman MS; Hartung HP; Miller D; Montalban X; Kappos L; Edan G; Pleimes D; Beckman K; Stemper B; Polman CH; Sandbrink R; Barkhof F
Mult Scler; 2014 Feb; 20(2):234-42. PubMed ID: 23842212
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F
Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165
[TBL] [Abstract][Full Text] [Related]
15. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
Hartung HP; Freedman MS; Polman CH; Edan G; Kappos L; Miller DH; Montalbán X; Barkhof F; Petkau J; White R; Sahajpal V; Knappertz V; Beckmann K; Lanius V; Sandbrink R; Pohl C;
Neurology; 2011 Aug; 77(9):835-43. PubMed ID: 21849647
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b.
Lazzaro C; Bianchi C; Peracino L; Zacchetti P; Uccelli A
Neurol Sci; 2009 Feb; 30(1):21-31. PubMed ID: 19169625
[TBL] [Abstract][Full Text] [Related]
17. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
[TBL] [Abstract][Full Text] [Related]
18. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
Ebers GC; Traboulsee A; Li D; Langdon D; Reder AT; Goodin DS; Bogumil T; Beckmann K; Wolf C; Konieczny A;
J Neurol Neurosurg Psychiatry; 2010 Aug; 81(8):907-12. PubMed ID: 20562430
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.
Caloyeras JP; Zhang B; Wang C; Eriksson M; Fredrikson S; Beckmann K; Knappertz V; Pohl C; Hartung HP; Shah D; Miller JD; Sandbrink R; Lanius V; Gondek K; Russell MW
Clin Ther; 2012 May; 34(5):1132-44. PubMed ID: 22541587
[TBL] [Abstract][Full Text] [Related]
20. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Cree BAC; Bowen JD; Hartung HP; Vermersch P; Hughes B; Damian D; Hyvert Y; Dangond F; Galazka A; Grosso M; Jones DL; Leist TP
Mult Scler Relat Disord; 2021 Apr; 49():102695. PubMed ID: 33578191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
